Dynavax Investor Relations Material

Dynavax Technologies Corporation is a biopharmaceutical company focused on developing and commercializing novel vaccines in the United States. The company's lead product in clinical development are therapeutic vaccines for Human Papillomavirus (HPV) Types 16 and 18, which can prevent cervical cancer; and therapeutic vaccine for Neisseria meningitidis serogroup B (MenB), which can prevent invasive meningococcal disease. Its product candidates include Hepatitis B Toxin Alpha subunit alone and with adjuvants, as well as HIV Encephalitis Virus (HEV) Capsid Protein Vaccine Technology that utilize Aptamer technology.